Semaglutide | GLP-1 Research Peptide
AUD $200
For laboratory research use only. Not for human use.
Research-grade Semaglutide — the GLP-1 receptor agonist approved as Ozempic (diabetes) and Wegovy (obesity). Studied for metabolic disease, cardiovascular outcomes, and weight management research. Third-party HPLC tested. For laboratory research use only.
Supply Specifications
| Peptide | Semaglutide |
| Mechanism | GLP-1 receptor agonist |
| Format | Lyophilised powder |
| Purity | ≥98% by HPLC |
| Testing | Third-party HPLC + Mass Spec |
| Storage | -20°C lyophilised |
| Use | Laboratory research use only |
| Price | AUD $200 |
Research Summary
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It is approved as Ozempic for type 2 diabetes and Wegovy for obesity. In the STEP-1 trial, participants achieved approximately 14.9% mean body weight reduction over 68 weeks.
Semaglutide is approved on the ARTG in Australia as Ozempic and Rybelsus. Research-grade Semaglutide from PeptideIQ is supplied for laboratory research use only, not for therapeutic use.
Related Research
Disclaimer: All products supplied by PeptideIQ are for laboratory research use only. They are not approved for human use, consumption, or therapeutic application. PeptideIQ complies with all applicable Australian regulations including the Therapeutic Goods Act 1989.